One-on-One
Cancer survivor & doctor discuss her transformative journey
Clip: Season 2026 Episode 2972 | 10m 55sVideo has Closed Captions
Cancer survivor & doctor discuss her transformative journey
Steve Adubato speaks with Debi Weiss, Lymphoma Cancer Survivor, and Charles Farber, MD, PhD, Hematologist-Oncologist at Atlantic Health, about Debi’s cancer journey and how innovative immunotherapy transformed her treatment and prognosis.
Problems playing video? | Closed Captioning Feedback
Problems playing video? | Closed Captioning Feedback
One-on-One is a local public television program presented by NJ PBS
One-on-One
Cancer survivor & doctor discuss her transformative journey
Clip: Season 2026 Episode 2972 | 10m 55sVideo has Closed Captions
Steve Adubato speaks with Debi Weiss, Lymphoma Cancer Survivor, and Charles Farber, MD, PhD, Hematologist-Oncologist at Atlantic Health, about Debi’s cancer journey and how innovative immunotherapy transformed her treatment and prognosis.
Problems playing video? | Closed Captioning Feedback
Where to Watch One-on-One
One-on-One is available to stream on pbs.org and the PBS app.
Providing Support for PBS.org
Learn Moreabout PBS online sponsorship(upbeat music) - Welcome back, folks.
We're going to be talking about CAR T-cell therapy with two people who know it from different perspectives, but know it well.
Debi Weiss is a lymphoma cancer survivor, and Dr.
Charles Farber is a hematologist and oncologist at Atlantic Health.
Full disclosure, Atlantic Health is one of our healthcare underwriters.
Great to have you with us.
Debi, talk to us.
I'm sorry for interrupting.
Back in January of 2024, you thought you had the flu.
It was not the flu.
- No.
- Talk to us.
- So I didn't feel well.
I though it was the flu.
Like everything else, I figured it would just go away.
It turned out that I got sicker and sicker and wound up being diagnosed with large B-cell lymphoma.
- Dr.
Farber, when you first met Debi, how clear was it to you what she was dealing with?
- Well, it was suspected, not entirely clear.
Debi had, as I recall, seeing her for the first time in the emergency department, a very large mass in her left neck.
She appeared to me to be chronically ill, had lost weight, wasn't eating well.
So we needed to take the next step, the gold standard, and that's obtain a biopsy and a true diagnosis.
- And Debi, did you go through chemotherapy?
- Yes.
- How effective was it?
- I thought it was really effective.
I did two rounds of chemo while in the hospital, four rounds as an outpatient.
And when those were finished, I actually thought I was done and was going to be able to resume my life.
- And Dr.
Farber, what was really going on and where does CAR-T cell therapy come into the equation for Debi?
- Sure thing.
I agree with Debi.
She did fabulous.
She achieved a complete remission, but unfortunately complete remissions are not equatable with cures.
And as I recall, about one or two months after completing her therapy, being in remission, she developed some neurologic issues.
So unfortunately, she had recurred in her brain.
There's something called- - One second.
I'm sorry for interrupting.
Debi, you were having severe headaches, correct?
- Yes.
- Okay.
I'm sorry for interrupting, doctor.
Go ahead.
- No, that's okay.
She presented, I think she had some confusion as well as the significant headaches.
And on further investigation imaging, we found that she had a large mass within her cranium.
Biopsy revealed a recurrence.
There's something called the blood-brain barrier.
So the chemotherapy you give in the vein doesn't penetrate the brain.
It's a sanctuary and unfortunately, it weathered the earlier chemotherapy.
So she had recurred.
- First of all, what is CAR T-cell therapy A and B?
How does it become the protocol for Debi in this particular case?
- Sure.
So CAR T is an acronym.
It stands for chimeric antigen receptor T-cells.
It's a medical technology or procedure we do.
It's mostly used currently for patients with relapsed refractory hematologic malignancies, such as Debi had diffuse large B-cell lymphoma, but also multiple myeloma, acute lymphoblastic leukemia.
And now we're even using it in autoimmune disorders.
At any rate, what this involves is collecting a subset of white blood cells from the patient, Debi.
We ship them to a facility, a special laboratory that genetically modifies.
It engineers Debi's own cells, the patient's own cells to do what those cells had not been able to do earlier, eliminate the cancer.
The cells, after they're genetically modified and expanded in terms of the numbers of them are shipped back to the treating physicians here at Morristown Medical Center.
And then we prepare Debi and give her her own cells back that have been modified in such a way that they're now very active against this cancer.
- Before I come back to Debi, Doctor, how long has CAR T-cell therapy been around?
- Well, it was first developed in the early 2010s, was pioneered at University of Pennsylvania, but it's come into more widespread use the last three or four years, and it's a very exciting technology.
- Debi, what was your response to the CAR T-cell therapy?
- In terms of my health or in terms of my emotional?
- Well, you can go wherever you want with it.
- Okay.
So I looked at all of the information that Dr.
Farber gave me and realized this was something I wanted to do.
I was extremely fortunate.
I went through this without very many side effects at all, and it was pretty fascinating.
Being a person who is very interested in the body and biology, I found it to be one of the most interesting things.
It was almost like they gave me my cells back and they were like little Pac-Men and they just went in and did their job and I'm fine.
- When you say you're fine, the tests, several months after, I believe three months after, the scans showed no sign of cancer?
- Correct.
- Doctor, so help us understand this.
When the test came back that there was no sign of cancer, that Debi did not have any signs of cancer, was the cancer cured, Doctor?
- Unfortunately, only time can say that a patient's cured, but she is in a complete clinical remission.
There's no evidence of disease.
Her clinical status has improved to the point that she's at her baseline where she was perhaps a couple years ago.
- Sure.
- So she's doing fabulous from my perspective.
- And Debi, from your perspective, describe your life style.
- I'm a pretty active person.
So prior to being diagnosed with lymphoma, I was a very healthy 70-year-old woman that just happened to be diagnosed with cancer.
Since the CAR T, my life has gone back pretty much to where it was before.
I'm working, I'm a Pilates teacher and I work in a retail store part-time.
I walk.
Unfortunately, I recently had an accident, so I fell and broke my wrist and my hip, but that's being dealt with on a different level.
I truly believe that I will be fine.
- You're a Pilates instructor?
- Mm-hmm.
- I've been doing it for 10 years.
Why can't I figure out the Reformer?
(all laughing) I'm sorry.
Doctor, before I let you go, how about people are wondering right now, who is a candidate for CAR T-cell therapy and who is not, Doctor?
- Sure.
Well, it casts a wide net that most patients who require it are appropriate.
So certainly for patients with many of the hematologic malignancies who recur sort of early on after their initial remission or those who don't achieve a complete remission to start off with.
So widespread, we're using it for diffuse large B-cell lymphoma, multiple myeloma and ALL, but also autoimmune diseases, we're branching out and it's being used for non-malignant conditions.
Lupus, I'm sorry.
- No, no.
Doctor, not cheap though.
- No, it is expensive.
We tend not to focus on that, but you're absolutely correct.
These technologies come at a cost, but this is a tremendously beneficial technology and it fulfills an unmet need.
So Debi would not have been in very good shape with the other conventional treatments for her condition.
So you are correct.
It is pricey and fortunately insurance for most patients does cover it because it's so effective.
- Medicine is pricey, but important.
Debi, 30 seconds.
Advice for others.
- My biggest advice, and I say this all the time, is you have to have faith in your doctors and your medical team.
So I met Dr.
Farber at the very beginning of my journey.
He has taken me from being extremely sick to being extremely healthy and I trust him implicitly.
So if you don't have that kind of faith in your medical team, find another medical team.
- Debi, wish you all the best.
Thank you for joining us.
Dr.
Farber, thank you as well.
And all good things.
- Thank you.
- That's what we wish you, Debi.
- Thank you so much.
- Thank you.
- You got it.
Stay with us, we'll be right back.
- [Narrator] One-On-One with Steve Adubato is a production of the Caucus Educational Corporation.
Funding has been provided by EJI, Excellence in Medicine.
A New Jersey health foundation program.
The Adubato Center for Media Leadership.
Valley Bank.
Newark Board of Education.
New Jersey Board of Public Utilities.
Robert Wood Johnson Foundation.
The North Ward Center.
PSEG Foundation.
And by New Jersey Sharing Network.
Promotional support provided by Meadowlands Chamber.
And by Insider NJ.
- Are you looking to be a part of a dynamic, forward-thinking business service organization?
At Meadowlands Chamber, every day we connect, collaborate and innovate, helping to drive business and economic growth in the greater Meadowlands and New Jersey.
I invite you to visit our Meadowlands Chamber headquarters, an open office facility with access to resources for our members' businesses and networking needs.
Together, we will build the chamber of the future, and the next generation of leaders.
Back to One — Return to Ground Zero: Loss and healing
Video has Closed Captions
Clip: S2026 Ep2972 | 7m 18s | Back to One — Return to Ground Zero: Loss and healing (7m 18s)
Why social media rewards negative content
Video has Closed Captions
Clip: S2026 Ep2972 | 9m 2s | Why social media rewards negative content (9m 2s)
Providing Support for PBS.org
Learn Moreabout PBS online sponsorship
New Episode- News and Public Affairs

Top journalists deliver compelling original analysis of the hour's headlines.
New Episode- News and Public Affairs

Today's top journalists discuss Washington's current political events and public affairs.


New Episode
New Episode
New Episode
New Episode

New Episode


Support for PBS provided by:
One-on-One is a local public television program presented by NJ PBS


